Communiqués Mosaic ImmunoEngineering, Inc.

Actions

CPMV

US61945M1018

Recherche biotechnologique et médicale

Marché Fermé - OTC Markets 15:59:58 08/09/2026			Varia. 5j.	Varia. 1 janv.
0,0850 ^USD	+39,34%		0,00%	-72,67%

14/08	Mosaic ImmunoEngineering, Inc. publie ses résultats pour le deuxième trimestre et le premier semestre clos le 30 juin 2026	CI
20/05	Mosaic ImmunoEngineering, Inc. publie ses résultats pour le premier trimestre clos le 31 mars 2026	CI

Communiqués

29/04/24	Oncotelic Therapeutics, Inc. to Sell Its Necroptosis Cancer Therapy Assets to Mosaic ImmunoEngineering, Inc.	AQ
28/03/24	Mosaic ImmunoEngineering : Termination of Material Agreement - Form 8-K	PU
03/05/23	MOSAIC IMMUNOENGINEERING INC. : Change in Directors or Principal Officers (form 8-K)	AQ
02/03/23	MOSAIC IMMUNOENGINEERING INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
01/11/22	MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
04/08/22	MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
12/07/22	MOSAIC IMMUNOENGINEERING INC. : Entry into a Material Definitive Agreement, Financial Statements and Exhibits (form 8-K)	AQ
10/05/22	MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
05/05/22	MOSAIC IMMUNOENGINEERING INC. : Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	AQ
22/02/22	MOSAIC IMMUNOENGINEERING INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Financial Statements and Exhibits (form 8-K)	AQ
02/02/22	Mosaic ImmunoEngineering : Newly Published Data Further Support Mosaic ImmunoEngineering’s Lead Immuno-Oncology Candidate MIE-101 in Combination with OX40 Checkpoint Treatment in Melanoma	PU
26/01/22	MOSAIC IMMUNOENGINEERING INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-K)	AQ
02/11/21	MOSAIC IMMUNOENGINEERING INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
01/11/21	Mosaic ImmunoEngineering’s Lead Immuno-Oncology Candidate MIE-101 Highlighted in Keynote Presentation	PU
20/10/21	Mosaic ImmunoEngineering Announces Upcoming Presentation at the 23rd Annual SoCalBio Conference	PU
12/10/21	Spotlight Presentation at the World Molecular Imaging Congress Highlights Mosaic ImmunoEngineering’s Immuno-Oncology and Modular Vaccine Platform Candidates	PU
03/08/21	MOSAIC IMMUNOENGINEERING : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
15/06/21	Mosaic ImmunoEngineering : Elects Biotechnology Industry Veteran Robert A. Baffi, Ph.D. to Its Board of Directors (Form 8-K)	PU
15/06/21	MOSAIC IMMUNOENGINEERING INC. : Change in Directors or Principal Officers, Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)	AQ
12/05/21	Mosaic ImmunoEngineering : Form of Convertible Note Purchase Agreement (Form 8-K)	PU
10/05/21	MOSAIC IMMUNOENGINEERING INC. : Entry into a Material Definitive Agreement, Unregistered Sale of Equity Securities, Financial Statements and Exhibits (form 8-K)	AQ
05/05/21	MOSAIC IMMUNOENGINEERING : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q)	AQ
02/03/21	Mosaic ImmunoEngineering : Annual Transition Report (SEC Filing - 10-KT)	PU
02/03/21	MOSAIC IMMUNOENGINEERING : 10-KT - MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	AQ
30/12/20	MOSAIC IMMUNOENGINEERING INC. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)	AQ